Ditzel HM, et al. - In the current study, researchers independently assessed chemotherapy response score (CRS) system which has recently been thought to be able to evaluate the histopathologic response and prognosis of patients with tubo-ovarian high-grade serous carcinoma (HGSC) receiving neoadjuvant chemotherapy. They included a total of 68 patients with omental (n=65) and/or adnexal (n=59) slides in the study. Thirteen pathologists independently scored slides using the 3-tiered CRS system. Outcomes support the potential utility of the three-tiered CRS system of hemotoxylin and eosin–stained omental deposits for attaining prognostic information for HGSC patients receiving neoadjuvant chemotherapy. They observed improved reproducibility but no change in the determination of clinical outcomes with web-based training. It seems with the help of this CRS system, oncologists may recognize potential nonresponders and triage HGSC patients for more observation and/or clinical trials.